Quick Answer
BIOTRICITY INC. reported Research And Development Expense of $2.16 million for the year ending 2025.
- BIOTRICITY INC. showed a decrease of -16.2% in Research And Development Expense from 2024 to 2025.
- This data is from BIOTRICITY INC.'s annual report (Form 10-K), filed with the SEC on July 15, 2025.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $326.2 thousand | Q1 2016: $241.5 thousand | Q2 2016: $266.4 thousand | Q3 2016: $248.0 thousand | Q4 2016: $333.6 thousand | Q2 2017: $315.1 thousand | Q3 2017: $413.6 thousand | Q4 2017: $377.9 thousand | Q2 2018: $309.9 thousand | Q3 2018: $401.3 thousand | Q4 2018: $401.3 thousand | Q2 2019: $213.5 thousand | Q3 2019: $218.5 thousand | Q4 2019: $447.6 thousand | Q2 2020: $423.9 thousand | Q3 2020: $402.3 thousand | Q4 2020: $681.4 thousand | Q2 2021: $589.0 thousand | Q3 2021: $625.6 thousand | Q4 2021: $900.5 thousand | Q2 2022: $821.2 thousand | Q3 2022: $828.9 thousand | Q4 2022: $876.5 thousand | Q2 2023: $713.0 thousand | Q3 2023: $697.6 thousand | Q4 2023: $453.0 thousand | Q2 2024: $513.9 thousand | Q3 2024: $518.0 thousand | Q4 2024: $551.2 thousand | Q2 2025: $696.2 thousand | Q3 2025: $602.8 thousand | Q4 2025: $623.6 thousand.
- Over the full 11 years of available data (2015 to 2025), BIOTRICITY INC.'s Research And Development Expense has grown by 88.5%.
- Historical annual values: Fiscal year 2025: $2.16 million | Fiscal year 2024: $2.57 million | Fiscal year 2023: $3.23 million | Fiscal year 2022: $2.74 million | Fiscal year 2021: $2.06 million | Fiscal year 2020: $1.36 million | Fiscal year 2019: $1.31 million | Fiscal year 2018: $1.76 million | Fiscal year 2017: $1.14 million | Fiscal year 2016: $1.09 million | Fiscal year 2015: $1.14 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: